Adc Therapeutics SA

NYSE:ADCT   11:52:00 AM EDT
28.21
+0.45 (+1.62%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.16B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$7.24 Million
Adjusted EPS-$0.89
See more estimates
10-Day MA$27.41
50-Day MA$25.25
200-Day MA$26.67
See more pivots

Adc Therapeutics SA Stock, NYSE:ADCT

Biopole, Route de la Corniche 3B, Epalinges, Vaud 1066
Switzerland
Phone: +41.212.653.02.00
Number of Employees: 208

Description

ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.